CALL GUIDE

The Health Technology Assessment (HTA) Philippines invites interested Filipino researchers to submit <u>capsule proposals</u> under the 2023 HTA) Research Agenda Program (HTA Research Topics 2023 - Batch 2).

The HTA Research Agenda 2023 - batch 2 consists of projects that aim:

- (1) to generate evidence for the development of HTA Council recommendations on coverage decisions for DOH and PhilHealth, using current HTA methodologies and,
- (2) to develop HTA Methods Guides specific to the assessment of health technologies classified as Medical and Surgical Procedures and for Preventive and Promotive Health.

HTA Research Agenda 2023 - Batch 2 topics

The following are the research topics to be funded under this Call for Capsule Proposals:

METHODS GUIDE DEVELOPMENT:

- 1. HTA Methods Guide for assessing health technologies classified as *Medical and Surgical Procedures*
- 2. HTA Methods Guide for assessing health technologies for Preventive and Promotive Health

Please refer to the attached Annex C for the details on the project objectives, suggested methodology, project duration, and budget allotment.

General Guidelines

- 1. There shall be two (2) stages in the proposal evaluation. The first is the submission of a capsule proposal, and the second is the submission of the full proposal. The full proposal is submitted only upon approval of the capsule proposal.
- 2. The capsule proposal should not be more than two (2) pages (Arial font 11, single spacing). Deadline for the submission of the capsule proposal and other requirements is 15 December 2023.
- 3. The capsule proposal shall be evaluated based on the following criteria:
 - a. Relevance & Sensitivity Alignment of the research questions and objectives to the research agenda

- b. Technical/Scientific Sound methodology; alignment to the research questions and HTA Methods Guide
- c. Data Management Technical merit on handling and management of data.
- d. Financial Feasibility Alignment of the projected project costs to the allocated budget for the research
- e. Proponent's / Institutional Capacity Good track record or CV with proven competence to implement and complete the project within the approved duration and budget.
- f. Conflict of interest (COI) No significant COI; following the COI declaration in the HTA Process Guide
- 4. The review process will take **2 weeks or less** provided that all the requirements have been submitted. The proponent may need to revise the capsule proposal on the basis of the recommendations of the reviewers.
- 5. Proponents of approved capsule proposals shall be notified to proceed to the submission of the full proposal *(details to be provided)*.

Note: These guidelines only refer to the review of capsule proposals. A separate set of guidelines shall be issued for the processing and approval of the full proposal.

Who may apply for the grant?

Filipinos with at least a Master's Degree in a relevant field, have proven research competence / track record, and employed in universities/colleges, research agencies/institutions, hospitals, and other health related agencies are eligible to apply for the research grant.

How to apply?

The interested researchers shall submit the following requirements to <a href="https://https://https://html.ncbi.nlm.ncb

- 1. Capsule proposal [Annex A; Link to downloadable template]
- 2. **COI declaration** of the primary investigator [Annex B; Link to template]
- 3. Cover Letter to the HTA Division DOST addressed to:

ANNE JULIENNE G. MARFORI, RPh, MSc

Chief, HTA Division

Department of Science and Technology

Deadline of submission of the above requirements: 15 December 2023

Any concerns or questions?

For any questions, comments or concerns, please email us at https://html.nc.nih.gov.ph:

ANNEX A - Template of Capsule Proposal

Title:	
Authors:	
Affiliations:	

- I. BACKGROUND:
- II. OBJECTIVES:
- III. METHODOLOGY:
- IV. ESTIMATED BUDGET
- V. DURATION OF PROJECT IMPLEMENTATION

Note: The capsule proposal should not be more than two (2) pages (Arial font 11, single spacing).

ANNEX B - COI Declaration Form

L.CURENT FINANCIAL INTERESTS To the best of your knowledge, do 1) you or any of your relative within the fourth (4") civil degree, by affinity or consanguinity, 2) organization in which you serve officer, director, trustee, general partner, or employee and/or 3) entity with whom you are negotiating or have any arrangement concerning prospective employs have any current involvement or financial link with any policy determining activity of the office/agency/advisory body/committee: a. INVESTMENTS (e.g. stocks, bonds, retirement plans, trust, partnerships, sector funds, etc.) TYPE OF INVESTMENT TYPE OF INVESTMENT (self, spouse, etc.) D. SHARES CURRENT VALUE LESS THAN 15% CHECK PERCENTAGE NET WORE THAN 15% CHARD PROCESTAGE THAN 15% CHECK PERCENTAGE THAN 15% CHECK PERCENTAGE THAN 15% CHECK PERCENTAGE THAN 15% THAN 15% CHECK PERCENTAGE THOMPORE THAN 15% THAN 15% CHECK PERCENTAGE THOMPORE THAN 15% CHECK PERCENTAGE THOMPORE THAN 15% CHECK PERCENTAGE THOMPORE THAN 15% THAN 15% CHECK PERCENTAGE THOMPORE THAN 15% THAN 15% CHECK PERCENTAGE THOMPORE THAN 15% THAN 15			
ESTABLISHMENT TYPE OF INVESTMENT (self, spouse, etc.) OWNER (self, spouse, etc.) OF SHARES CURRENT VALUE (SELF STABLISHMENT (Self, spouse, etc.) OF SHARES (SELF STABLISHMENT (Self, spouse, etc.) OWNER (Self, spouse, etc.) OWNER (SELF STABLISHMENT (Self, spouse, etc.) OWNER (Self, spouse, etc.) OWNER (SELF STABLISHMENT (Self, spouse, etc.) OWNER (Self, spouse, etc.) OWNER (Self, spouse, etc.) OWNER (SELF STABLISHMENT (Self, spouse, etc.) OWNER (SELF STABLISH (Self, spouse, etc.) O			
ESTABLISHMENT TYPE OF INVESTMENT (self, spouse, etc.) OWNER (self, spouse, etc.) OF SHARES CURRENT VALUE THAN 5% 5-15% THAN 15% 15% 15% 15% 15% 15% 15% 15% 15% 15%			
ESTABLISHMENT INVESTMENT (self, spouse, etc.) OF SHARES CURRENT VALUE THAN 5-15% THAN 15% Comparison of the compariso	CHECK PERCENTAGE NET WORTH		
ESTABLISHMENT RELATIONSHIP POSITION IN FIRM DATE EMPLOYMENT OR NEGOTIATIONS BEGAN C. CONSULTANT/ADVISOR (Current or Under Negotiation) BY NONE (If "none", skip to Item d.) RELATED TO LIST PRODUCTS/ INDICATIONS/	N		
ESTABLISHMENT RELATIONSHIP POSITION IN FIRM DATE EMPLOYMENT OR NEGOTIATIONS BEGAN C. CONSULTANT/ADVISOR (Current or Under Negotiation) BY NONE (If "none", skip to Item d.) RELATED TO LIST PRODUCTS/ INDICATIONS/			
ESTABLISHMENT RELATIONSHIP POSITION IN FIRM DATE EMPLOYMENT OR NEGOTIATIONS BEGAN C. CONSULTANT/ADVISOR (Current or Under Negotiation) BY NONE (If "none", skip to Item d.) RELATED TO LIST PRODUCTS/ INDICATIONS/			
C. CONSULTANT/ADVISOR (Current or Under Negotiation) ESTABLISHMENT TOPIC/ISSUE POSITION IN FIRM NEGOTIATIONS BEGAN			
ESTABLISHMENT TOPIC/ISSUE AMOUNT RECEIVED DATE PRODUCTS/INDICATIONS/			
ESTABLISHMENT TOPIC/ISSUE AMOUNT RECEIVED DATE PRODUCTS/INDICATIONS/	_		
ESTABLISHMENT TOPIC/ISSUE AMOUNT RECEIVED DATE PRODUCTS/INDICATIONS/	\dashv		
ESTABLISHMENT TOPIC/ISSUE AMOUNT RECEIVED DATE PRODUCTS/INDICATIONS/	<u> </u>		
d. CONTRACTS/GRANTS (Current or Under Negotiation)			
TYPE OF AGREEMENT (contract, grant) PRODUCT UNDER STUDY AND INDICATIONS AMOUNT OF REMUNERATION TO INSTITU-TI ON TIME PERIOD SPONSOR* YOUR ROLE** AWARDEE RELATED TO LISTED PRODUCTS/ INDICATIONS/ ISSUES	/		
□ YES □ NO			
□ YES □ NO			
□ YES □ NO			
□ YES □ NO			

* Government, Establishm ** Site Investigator, Princip			or, Employee, Part	ner. No Involv	vement. or Othe	er				
IF MORE SPACE IS NEEDED,										
1. CURRENT FINANCIAL INT			ALTAGES							
e. INTELLECTUAL PROPER	TY (PATENTS/R	OYALTIES/TR	RADEMARKS)		□ NC	ONE (If "r	none", skip	to Item f.)		
FOR ESTABLISHMENT			T	RELATED TO LISTED PRODUCTS/ INDICATIONS/ ISSUES		IF "YES", EXPLAIN BELOW AND INDICATE INCOME RECEIVED				
				□ YES □	ı NO					
				□ YES □	ı NO					
				□ YES □	ı NO					
f. EXPERT WITNESS (Last 12 appeared for or against the)	□ NO	NE (If "n	one", skip	to Item g.)		
FIRM AND ISSUE		AMOUNT RECEIVED		PRODUCT	TO LISTED TS/ ONS/ ISSUES		IF "YES", EXPLAIN BELOW AND INDICATE INCOME RECEIVED		ID	
				□ YES □	□ NO					
			□ YES □	□ NO						
				□ YES □	□ NO					
g. SPEAKING/WRITING (Last 12 Months or under negotiation) □ NONE (If "none", skip to Item 2.)										
			,	AMOUNT REC	CEIVED				REL	ATED TO LISTED
FIRM				TF	TRAVEL		I			ODUCTS/ DICATIONS/ ISSUES
□ YES □ NC					ES 🗆 NO					
□ YES □ NO					ES 🗆 NO					
					□ YES □ NO			ES □ NO		
2. PAST FINANCIAL INTERES a. To the best of your know an officer, director, truste body/committee:	vledge, do 1) yo									
□ YES		NO	_ I	NOT TO MY K	NOWLEDGE					
b. If "Yes." describe involver	nent.								1	RELATED TO LISTED
FIRM/PRODUCT FINANCIAL INVOLVEMENT (e.g. contract/consultant)				ROLE			DATES		PRODUCTS/ INDICATIONS/ ISSUES	
										□ YES □ NO
									\neg	□ YES □ NO

		□ YES □ NO					
		□ YES □ NO					
IF MORE SPACE IS NEEDED, PLEASE ATTACH ADDITIONAL PAGES							
3. OTHER INVOLVEMENTS (Other Kinds of Relationships) Using the list of products/firms/issues, identify anything that would give a lawsuit, researcher initiated study, gift of research materials, etc.).	ne", skip to Item 4.) In "appearance" of a conflict which has no	t been disclosed above (e.g. involvement in a					
_							
4. CERTIFICATION STATEMENT I, designated as	of the						
(First Name, MI, Family Name) (Position/Designation, when applicable) (Name of Agency, Office, Bureau, Service, Hospital, or Unit) do hereby declare on my honor that the above information is true and complete, to the best of my knowledge. If there are any changes, I will promptly notify you. This includes any change that occurs before or during the meeting or work itself and through the period up to the publication of the final results or completion of the activity concerned.							
My response contains pages.							
NAME AND SIGNATURE OF DECLARANT	DATE						
TANKE AND SIGNATURE OF DECEMBANT	Polic						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations.		ce with applicable conflict of interest with laws					
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic	s Committee (PHEC) to determine complian	ce with applicable conflict of interest with laws					
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required	s Committee (PHEC) to determine complian authorized by law.						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless	s Committee (PHEC) to determine complian authorized by law.						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY NAME AND SIGNATURE OF REVIEWING OFFICIAL	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY NAME AND SIGNATURE OF REVIEWING OFFICIAL	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						
CONFIDENTIALITY STATEMENT The primary use of this information is for review of the Public Health Ethic and regulations. This confidential report will not be disclosed to any requesting person, unless Falsification of information or failure to file or report of information required FOR PHEC USE ONLY NAME AND SIGNATURE OF REVIEWING OFFICIAL	s Committee (PHEC) to determine complian authorized by law. to be reported is subject to disciplinary acti						

ANNEX C - KEY DETAILS ON THE RESEARCH TOPICS

METHODS GUIDE DEVELOPMENT

No	Торіс	Objectives	Suggested Methodology	Project Duration	Budget
	HTA Methods Guide for assessing health technologies classified as Medical and Surgical Procedures	General objective: To develop a Health Technology Assessment Methods Guide for the assessment of health technologies classified as medical and surgical procedures Specific objectives: To review the current HTA Philippines Methods Guide and methodologies in other settings and to identify applicable methodologies relevant to the assessment of the clinical, economic, and ethical, legal, social, and health systems impact of medical and surgical procedures To identify or develop methods for the assessment of medical and surgical procedures To conduct expert consultation to validate the proposed assessment methodologies To draft a methodological framework for the assessment of medical and surgical procedures To validate the methodological framework through a pilot assessment of an existing medical and surgical procedure To develop a manuscript discussing the development of the methods guide that will be ready for journal publications	 Literature review of methodologies or HTA methods guide from other settings Critical appraisal of the applicability of methodologies to the Philippine setting Consultation with experts on the proposed methods Validation of drafted methods guide through the conduct of a pilot assessment 	6 months	Php 1,500,000.00

No	Торіс	Objectives	Suggested Methodology	Project Duration	Budget
2	HTA Methods Guide for assessing health technologies for Preventive and Promotive Health	General objective: To develop a Health Technology Assessment Methods Guide for the assessment of health technologies for preventive and promotive health. Specific objectives: 1. To review the current HTA Philippines Methods Guide and methodologies in other settings and to identify applicable methodologies relevant to the assessment of the clinical, economic, and ethical, legal, social, and health systems impact of preventive and promotive health technologies 2. To identify or develop methods for the assessment of preventive and promotive health technologies 3. To conduct expert consultation to validate the proposed assessment methodologies 4. To draft a methodological framework for the assessment of preventive and promotive health technologies 5. To validate the methodological framework through a pilot assessment of an existing preventive and promotive health technology 6. To develop a manuscript discussing the development of the methods guide that will be ready for journal publications	 Literature review of methodologies or HTA methods guide from other settings Critical appraisal of the applicability of methodologies to the Philippine setting Consultation with experts on the proposed methods Validation of drafted methods guide through the conduct of a pilot assessment 	6 months	Php 1,500,000.00